Myocardial matrix metalloproteinase-2: Inside out and upside down

Journal of Molecular and Cellular Cardiology

Volumn 77, Issue , 2014, Pages 64-72

  DeCoux, Ashley ^a   Lindsey, Merry L ^a,b   Villarreal, Francisco ^d   Garcia, Ricardo A ^c,d   Schulz, Richard ^e  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b G V SONNY MONTGOMERY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

^e UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cardiovascular disease; Doxycycline; Heart failure; MMP 2; Myocardial ischemia and infarction; TIPTOP

Indexed keywords

AGGRECAN; BETA1 INTEGRIN; COLLAGEN TYPE 1; COLLAGEN TYPE 2; DESMIN; DOXYCYCLINE; ELASTIN; ENDOTHELIN 1; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBRONECTIN; GALECTIN 3; GELATINASE A; GLYCOGEN SYNTHASE KINASE 3BETA; INTERLEUKIN 1BETA; KALININ; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN; MATRIX METALLOPROTEINASE INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN 3; MYELIN BASIC PROTEIN; MYOSIN LIGHT CHAIN; PG 116800; PROTEOCHONDROITIN SULFATE; SOMATOMEDIN BINDING PROTEIN; SUBSTANCE P; TENASCIN; TETRACYCLINE DERIVATIVE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VITRONECTIN; ISOENZYME; MMP2 PROTEIN, HUMAN;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; CARDIOVASCULAR DISEASE; CATALYSIS; CAVEOLA; CELL NUCLEUS; CELL ORGANELLE; CLINICAL TRIAL (TOPIC); COLLAGEN SYNTHESIS; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; ENZYME SUBSTRATE; EXTRACELLULAR MATRIX; HEART FAILURE; HEART INFARCTION; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; INTRACELLULAR TRANSPORT; MITOCHONDRION; NONHUMAN; PATHOGENESIS; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; REPERFUSION INJURY; REVIEW; ANIMAL; CARDIOVASCULAR DISEASES; ENZYMOLOGY; OXIDATIVE STRESS; PHYSIOLOGY; PROTEIN TRANSPORT;

ANIMALS; CARDIOVASCULAR DISEASES; EXTRACELLULAR MATRIX; HUMANS; ISOENZYMES; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE INHIBITORS; OXIDATIVE STRESS; PROTEIN TRANSPORT; PROTEOLYSIS;

EID: 84908389458     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2014.09.016     Document Type: Review

References (114)

1. Clark I.M., Swingler T.E., Sampieri C.L., Edwards D.R. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 2008, 40:1362-1378.
2. Chen Q., Jin M., Yang F., Zhu J., Xiao Q., Zhang L. Matrix metalloproteinases: inflammatory regulators of cell behaviors in vascular formation and remodeling. Mediators Inflamm 2013, 2013:928315.
3. Jacob-Ferreira A.L., Schulz R. Activation of intracellular matrix metalloproteinase-2 by reactive oxygen-nitrogen species: Consequences and therapeutic strategies in the heart. Arch Biochem Biophys 2013, 540:82-93.
4. Perlikos F., Harrington K.J., Syrigos K.N. Key molecular mechanisms in lung cancer invasion and metastasis: a comprehensive review. Crit Rev Oncol Hematol 2013, 87:1-11.
5. Woessner J.F. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991, 5:2145-2154.
6. Schonbeck U., Mach F., Libby P. Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J Immunol 1998, 161:3340-3346.
7. Ito A., Mukaiyama A., Itoh Y., Nagase H., Thogersen I.B., Enghild J.J., et al. Degradation of interleukin 1beta by matrix metalloproteinases. J Biol Chem 1996, 271:14657-14660.
8. Wang W., Schulze C.J., Suarez-Pinzon W.L., Dyck J.R., Sawicki G., Schulz R. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 2002, 106:1543-1549.
9. Lopez-Otin C., Overall C.M. Protease degradomics: a new challenge for proteomics. Nat Rev Mol Cell Biol 2002, 3:509-519.
10. Cauwe B., Opdenakker G. Intracellular substrate cleavage: a novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases. Crit Rev Biochem Mol Biol 2010, 45:351-423.
11. Sawicki G., Leon H., Sawicka J., Sariahmetoglu M., Schulze C.J., Scott P.G., et al. Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: a new intracellular target for matrix metalloproteinase-2. Circulation 2005, 112:544-552.
12. Thygesen K., Alpert J.S., Jaffe A.S., Simoons M.L., Chaitman B.R., White H.D., et al. Third universal definition of myocardial infarction. J Am Coll Cardiol 2012, 60:1581-1598.
13. Hori M., Nishida K. Oxidative stress and left ventricular remodelling after myocardial infarction. Cardiovasc Res 2009, 81:457-464.
14. Doucet A., Butler G.S., Rodriguez D., Prudova A., Overall C.M. Metadegradomics: toward in vivo quantitative degradomics of proteolytic post-translational modifications of the cancer proteome. Mol Cell Proteomics 2008, 7:1925-1951.
15. Schilling O., Overall C.M. Proteome-derived, database-searchable peptide libraries for identifying protease cleavage sites. Nat Biotechnol 2008, 26:685-694.
16. Yasmin W., Strynadka K.D., Schulz R. Generation of peroxynitrite contributes to ischemia-reperfusion injury in isolated rat hearts. Cardiovasc Res 1997, 33:422-432.
17. Ferdinandy P., Danial H., Ambrus I., Rothery R.A., Schulz R. Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. Circ Res 2000, 87:241-247.
18. Pacher P., Beckman J.S., Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007, 87:315-424.
19. Okamoto T., Akaike T., Sawa T., Miyamoto Y., van der Vliet A., Maeda H. Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation. J Biol Chem 2001, 276:29596-29602.
20. Viappiani S., Nicolescu A.C., Holt A., Sawicki G., Crawford B.D., Leon H., et al. Activation and modulation of 72kDa matrix metalloproteinase-2 by peroxynitrite and glutathione. Biochem Pharmacol 2009, 77:826-834.
21. Jacob-Ferreira A.L., Kondo M.Y., Baral P.K., James M.N., Holt A., Fan X., et al. Phosphorylation status of 72 kDa MMP-2 determines its structure and activity in response to peroxynitrite. PLoS One 2013, 8:e71794.
22. Cheung P.-Y., Sawicki G., Wozniak M., Wang W., Radomski M.W., Schulz R. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 2000, 101:1833-1839.
23. Schulze C.J., Wang W., Suarez-Pinzon W.L., Sawicka J., Sawicki G., Schulz R. Imbalance between tissue inhibitor of metalloproteinase-4 and matrix metalloproteinases during acute myoctardial ischemia-reperfusion injury. Circulation 2003, 107:2487-2492.
24. Donnini S., Monti M., Roncone R., Morbidelli L., Rocchigiani M., Oliviero S., et al. Peroxynitrite inactivates human-tissue inhibitor of metalloproteinase-4. FEBS Lett 2008, 582:1135-1140.
25. Galvez A.S., Diwan A., Odley A.M., Hahn H.S., Osinska H., Melendez J.G., et al. Cardiomyocyte degeneration with calpain deficiency reveals a critical role in protein homeostasis. Circ Res 2007, 100:1071-1078.
26. Bergman M.R., Teerlink J.R., Mahimkar R., Li L., Zhu B.Q., Nguyen A., et al. Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. Am J Physiol Heart Circ Physiol 2007, 292:H1847-H1860.
27. Sung M.M., Schulz C.G., Wang W., Sawicki G., Bautista-Lopez N.L., Schulz R. Matrix metalloproteinase-2 degrades the cytoskeletal protein alpha-actinin in peroxynitrite mediated myocardial injury. J Mol Cell Cardiol 2007, 43:429-436.
28. Ali M.A., Cho W.J., Hudson B., Kassiri Z., Granzier H., Schulz R. Titin is a target of matrix metalloproteinase-2: implications in myocardial ischemia/reperfusion injury. Circulation 2010, 122:2039-2047.
29. Warren C.M., Jordan M.C., Roos K.P., Krzesinski P.R., Greaser M.L. Titin isoform expression in normal and hypertensive myocardium. Cardiovasc Res 2003, 59:86-94.
30. Grimes C.A., Jope R.S. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 2001, 65:391-426.
31. Woodgett J.R. Recent advances in the protein kinase B signaling pathway. Curr Opin Cell Biol 2005, 17:150-157.
32. Goni-Oliver P., Lucas J.J., Avila J., Hernandez F. N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation. J Biol Chem 2007, 282:22406-22413.
33. Gross E.R., Gross G.J. Pharmacologic therapeutics for cardiac reperfusion injury. Expert Opin Emerg Drugs 2007, 12:367-388.
34. Gross E.R., Hsu A.K., Gross G.J. Delayed cardioprotection afforded by the glycogen synthase kinase 3 inhibitor SB-216763 occurs via a KATP- and MPTP-dependent mechanism at reperfusion. Am J Physiol Heart Circ Physiol 2008, 294:H1497-H1500.
35. Kandasamy A.D., Schulz R. Glycogen synthase kinase-3beta is activated by matrix metalloproteinase-2 mediated proteolysis in cardiomyoblasts. Cardiovasc Res 2009, 83:698-706.
36. Lovett D.H., Mahimkar R., Raffai R.L., Cape L., Maklashina E., Cecchini G., et al. A novel intracellular isoform of matrix metalloproteinase-2 induced by oxidative stress activates innate immunity. PLoS One 2012, 7:e34177.
37. Raturi A., Simmen T. Where the endoplasmic reticulum and the mitochondrion tie the knot: the mitochondria-associated membrane (MAM). Biochim Biophys Acta 1833, 2013:213-224.
38. Hughes B.G., Fan X., Cho W.J., Schulz R. MMP-2 is localized to the mitochondria-associated membrane of the heart. Am J Physiol Heart Circ Physiol 2014, 306:H764-H770.
39. Kwan J.A., Schulze C.J., Wang W., Leon H., Sariahmetoglu M., Sung M., et al. Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro. FASEB J 2004, 18:690-692.
40. Chow A.K., Daniel E.E., Schulz R. Cardiac function is not significantly diminished in hearts isolated from young caveolin-1 knockout mice. Am J Physiol Heart Circ Physiol 2010, 299:H1183-H1189.
41. Chow A.K., Cena J., El-Yazbi A.F., Crawford B.D., Holt A., Cho W.J., et al. Caveolin-1 inhibits matrix metalloproteinase-2 activity in the heart. J Mol Cell Cardiol 2007, 42:896-901.
42. Ali M.A., Chow A.K., Kandasamy A.D., Fan X., West L.J., Crawford B.D., et al. Mechanisms of cytosolic targeting of matrix metalloproteinase-2. J Cell Physiol 2012, 227:3397-3404.
43. Lovett D.H., Mahimkar R., Raffai R.L., Cape L., Zhu B.Q., Jin Z.Q., et al. N-terminal truncated intracellular matrix metalloproteinase-2 induces cardiomyocyte hypertrophy, inflammation and systolic heart failure. PLoS One 2013, 8:e68154.
44. Sariahmetoglu M., Crawford B.D., Leon H., Sawicka J., Li L., Ballermann B.J., et al. Regulation of matrix metalloproteinase-2 (MMP-2) activity by phosphorylation. FASEB J 2007, 21:2486-2495.
45. Sariahmetoglu M., Skrzypiec-Spring M., Youssef N., Jacob-Ferreira A.L., Sawicka J., Holmes C., et al. Phosphorylation status of matrix metalloproteinase-2 in myocardial ischaemia-reperfusion injury. Heart 2012, 98:656-662.
46. Cadete V.J., Sawicka J., Jaswal J.S., Lopaschuk G.D., Schulz R., Szczesna-Cordary D., et al. Ischemia/reperfusion-induced myosin light chain 1 phosphorylation increases its degradation by matrix metalloproteinase-2. FEBS J 2012, 279:2444-2454.
47. Ruetten H., Badorff C., Ihling C., Zeiher A.M., Dimmeler S. Inhibition of caspase-3 improves contractile recovery of stunned myocardium, independent of apoptosis-inhibitory effects. J Am Coll Cardiol 2001, 38:2063-2070.
48. Khalil P.N., Neuhof C., Huss R., Pollhammer M., Khalil M.N., Neuhof H., et al. Calpain inhibition reduces infarct size and improves global hemodynamics and left ventricular contractility in a porcine myocardial ischemia/reperfusion model. Eur J Pharmacol 2005, 528:124-131.
49. Castro M.M., Fuah J., Ali M., Sung M., Schulz J., Kondo M.Y., et al. Inhibitory effects of caspase inhibitors on the activity of matrix metalloproteinase-2. Biochem Pharmacol 2013, 86:469-475.
50. Ali M.A., Stepanko A., Fan X., Holt A., Schulz R. Calpain inhibitors exhibit matrix metalloproteinase-2 inhibitory activity. Biochem Biophys Res Commun 2012, 423:1-5.
51. Wilson E.M., Spinale F.G. Myocardial remodelling and matrix metalloproteinases in heart failure: turmoil within the interstitium. Ann Med 2001, 33:623-634.
52. Spinale F.G., Wilbur N.M. Matrix metalloproteinase therapy in heart failure. Curr Treat Options Cardiovasc Med 2009, 11:339-346.
53. Spinale F.G. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007, 87:1285-1342.
54. Yabluchanskiy A., Li Y., Chilton R.J., Lindsey M.L. Matrix metalloproteinases: drug targets for myocardial infarction. Curr Drug Targets 2013, 14:276-286.
55. Iyer R.P., de Castro Bras L.E., Jin Y.F., Lindsey M.L. Translating Koch's postulates to identify matrix metalloproteinase roles in postmyocardial infarction remodeling: cardiac metalloproteinase actions (CarMA) postulates. Circ Res 2014, 114:860-871.
56. Etoh T., Joffs C., Deschamps A.M., Davis J., Dowdy K., Hendrick J., et al. Myocardial and interstitial matrix metalloproteinase activity after acute myocardial infarction in pigs. Am J Physiol 2001, 281:H987-H994.
57. Sahul Z.H., Mukherjee R., Song J., McAteer J., Stroud R.E., Dione D.P., et al. Targeted imaging of the spatial and temporal variation of matrix metalloproteinase activity in a porcine model of postinfarct remodeling: relationship to myocardial dysfunction. Circ Cardiovasc Imaging 2011, 4:381-391.
58. Hutchinson K.R., Stewart J.A., Lucchesi P.A. Extracellular matrix remodeling during the progression of volume overload-induced heart failure. J Mol Cell Cardiol 2010, 48:564-569.
59. Nagatomo Y., Carabello B.A., Coker M.L., McDermott P.J., Nemoto S., Hamawaki M., et al. Differential effects of pressure or volume overload on myocardial MMP levels and inhibitory control. Am J Physiol 2000, 278:H151-H161.
60. Spinale F.G., Coker M.L., Thomas C.V., Walker J.D., Mukherjee R., Hebbar L. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ Res 1998, 82:482-495.
61. Lindsey M.L., Zamilpa R. Temporal and spatial expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases following myocardial infarction. Cardiovasc Ther 2012, 30:31-41.
62. Thomas C.V., Coker M.L., Zellner J.L., Handy J.R., Crumbley A.J., Spinale F.G. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 1998, 97:1708-1715.
63. Gunja-Smith Z., Morales A.R., Romanelli R., Woessner J.F. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy Role of metalloproteinases and pyridinoline cross-links. Am J Pathol 1996, 148:1639-1648.
64. Spinale F.G. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 2002, 90:520-530.
65. Yan A.T., Yan R.T., Spinale F.G., Afzal R., Gunasinghe H.R., Arnold M., et al. Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure. J Card Fail 2006, 12:514-519.
66. Borlaug B.A., Paulus W.J. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J 2011, 32:670-679.
67. Dorman G., Kocsis-Szommer K., Spadoni C., Ferdinandy P. MMP inhibitors in cardiac diseases: an update. Recent Pat Cardiovasc Drug Discov 2007, 2:186-194.
68. Hudson M.P., Armstrong P.W., Ruzyllo W., Brum J., Cusmano L., Krzeski P., et al. Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J Am Coll Cardiol 2006, 48:15-20.
69. Griffin M.O., Fricovsky E., Ceballos G., Villarreal F. Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell Physiol. 2010, 299:C539-C548.
70. Golub L.M., Lee H.M., Lehrer G., Nemiroff A., McNamara T.F., Kaplan R., et al. Minocycline reduces gingival collagenolytic activity during diabetes Preliminary observations and a proposed new mechanism of action. J Periodontal Res 1983, 18:516-526.
71. Lalu M.M., Pasini E., Schulze C.J., Ferrari-Vivaldi M., Ferrari-Vivaldi G., Bachetti T., et al. Ischaemia-reperfusion injury activates matrix metalloproteinases in the human heart. Eur Heart J 2005, 26:27-35.
72. Garcia R.A., Pantazatos D.P., Gessner C.R., Go K.V., Woods V.L., Villarreal F.J. Molecular interactions between matrilysin and the matrix metalloproteinase inhibitor doxycycline investigated by deuterium exchange mass spectrometry. Mol Pharmacol 2005, 67:1128-1136.
73. Villarreal F.J., Griffin M., Omens J., Dillmann W., Nguyen J., Covell J. Early short-term treatment with doxycycline modulates postinfarction left ventricular remodeling. Circulation 2003, 108:1487-1492.
74. Villarreal F., Omens J., Dillmann W., Risteli J., Nguyen J., Covell J. Early degradation and serum appearance of type I collagen fragments after myocardial infarction. J Mol Cell Cardiol 2004, 36:597-601.
75. Garcia R.A., Go K.V., Villarreal F.J. Effects of timed administration of doxycycline or methylprednisolone on post-myocardial infarction inflammation and left ventricular remodeling in the rat heart. Mol Cell Biochem 2007, 300:159-169.
76. Cerisano G., Buonamici P., Valenti R., Sciagra R., Raspanti S., Santini A., et al. Early short-term doxycycline therapy in patients with acute myocardial infarction and left ventricular dysfunction to prevent the ominous progression to adverse remodelling: the TIPTOP trial. Eur Heart J 2014, 35:184-191.
77. Gu Y., Walker C., Ryan M.E., Payne J.B., Golub L.M. Non-antibacterial tetracycline formulations: clinical applications in dentistry and medicine. J Oral Microbiol 2012, 4.
78. Phatharajaree W., Phrommintikul A., Chattipakorn N. Matrix metalloproteinases and myocardial infarction. Can J Cardiol 2007, 23:727-733.
79. Fan D., Creemers E.E., Kassiri Z. Matrix as an interstitial transport system. Circ Res 2014, 114:889-902.
80. Mast A.E., Enghild J.J., Nagase H., Suzuki K., Pizzo S.V., Salvesen G. Kinetics and physiologic relevance of the inactivation of alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, and antithrombin III by matrix metalloproteinases-1 (tissue collagenase), -2 (72-kDa gelatinase/type IV collagenase), and -3 (stromelysin). J Biol Chem 1991, 266:15810-15816.
81. Roher A.E., Kasunic T.C., Woods A.S., Cotter R.J., Ball M.J., Fridman R. Proteolysis of a beta peptide from Alzheimer disease brain by gelatinase A. Biochem Biophys Res Commun 1994, 205:1755-1761.
82. Miyazaki K., Hasegawa M., Funahashi K., Umeda M. A metalloproteinase inhibitor domain in Alzheimer amyloid protein precursor. Nature 1993, 362:839-841.
83. Fosang A.J., Neame P.J., Last K., Hardingham T.E., Murphy G., Hamilton J.A. The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B. J Biol Chem 1992, 267:19470-19474.
84. Zuo J., Ferguson T.A., Hernandez Y.J., Stetler-Stevenson W.G., Muir D. Neuronal matrix metalloproteinase-2 degrades and inactivates a neurite-inhibiting chondroitin sulfate proteoglycan. J Neurosci 1998, 18:5203-5211.
85. Aimes R.T., Quigley J.P. Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. J Biol Chem 1995, 270:5872-5876.
86. Berton A., Godeau G., Emonard H., Baba K., Bellon P., Hornebeck W., et al. Analysis of the ex vivo specificity of human gelatinases A and B towards skin collagen and elastic fibers by computerized morphometry. Matrix Biol 2000, 19:139-148.
87. Welgus H.G., Fliszar C.J., Seltzer J.L., Schmid T.M., Jeffrey J.J. Differential susceptibility of type X collagen to cleavage by two mammalian interstitial collagenases and 72-kDa type IV collagenase. J Biol Chem 1990, 265:13521-13527.
88. Brehmer B., Biesterfeld S., Jakse G. Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue. Prostate Cancer Prostatic Dis 2003, 6:217-222.
89. Azzam H.S., Thompson E.W. Collagen-induced activation of the M(r) 72,000 type IV collagenase in normal and malignant human fibroblastoid cells. Cancer Res 1992, 52:4540-4544.
90. Myint E., Brown D.J., Ljubimov A.V., Kyaw M., Kenney M.C. Cleavage of human corneal type VI collagen alpha 3 chain by matrix metalloproteinase-2. Cornea 1996, 15:490-496.
91. Kryczka J., Stasiak M., Dziki L., Mik M., Dziki A., Cierniewski C. Matrix metalloproteinase-2 cleavage of the beta1 integrin ectodomain facilitates colon cancer cell motility. J Biol Chem 2012, 287:36556-36566.
92. Fernandez-Patron C., Radomski M.W., Davidge S.T. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 1999, 85:906-911.
93. Kenny H.A., Kaur S., Coussens L.M., Lengyel E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest 2008, 118:1367-1379.
94. Levi E., Fridman R., Miao H.Q., Ma Y.S., Yayon A., Vlodavsky I. Matrix metalloproteinase-2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc Natl Acad Sci U S A 1996, 93:7069-7074.
95. Jiao Y., Feng X., Zhan Y., Wang R., Zheng S., Liu W., et al. Matrix metalloproteinase-2 promotes alphavbeta3 integrin-mediated adhesion and migration of human melanoma cells by cleaving fibronectin. PLoS One 2012, 7:e41591.
96. Ochieng J., Fridman R., Nangia-Makker P., Kleiner D.E., Liotta L.A., Stetler-Stevenson W.G., et al. Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9. Biochemistry 1994, 33:14109-14114.
97. Fowlkes J.L., Enghild J.J., Suzuki K., Nagase H. Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. J Biol Chem 1994, 269:25742-25746.
98. Fridman R., Toth M., Pena D., Mobashery S. Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res 1995, 55:2548-2555.
99. Giannelli G., Brassard J., Foti C., Stetler-Stevenson W.G., Falk-Marzillier J., Zambonin-Zallone A., et al. Altered expression of basement membrane proteins and their integrin receptors in lichen planus: possible pathogenetic role of gelatinases A and B. Lab Invest 1996, 74:1091-1104.
100. Giannelli G., Falk-Marzillier J., Schiraldi O., Stetler-Stevenson W.G., Quaranta V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 1997, 277:225-228.
101. Yu Q., Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 2000, 14:163-176.
102. Westermann D., Savvatis K., Lindner D., Zietsch C., Becher P.M., Hammer E., et al. Reduced degradation of the chemokine MCP-3 by matrix metalloproteinase-2 exacerbates myocardial inflammation in experimental viral cardiomyopathy. Circulation 2011, 124:2082-2093.
103. Chandler S., Coates R., Gearing A., Lury J., Wells G., Bone E. Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett 1995, 201:223-226.
104. Panchenko M.V., Stetler-Stevenson W.G., Trubetskoy O.V., Gacheru S.N., Kagan H.M. Metalloproteinase activity secreted by fibrogenic cells in the processing of prolysyl oxidase. Potential role of procollagen C-proteinase. J Biol Chem 1996, 271:7113-7119.
105. Knauper V., Will H., Lopez-Otin C., Smith B., Atkinson S.J., Stanton H., et al. Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme. J Biol Chem 1996, 271:17124-17131.
106. Crabbe T., O'Connell J.P., Smith B.J., Docherty A.J. Reciprocated matrix metalloproteinase activation: a process performed by interstitial collagenase and progelatinase A. Biochemistry 1994, 33:14419-14425.
107. Ellerbroek S.M., Wu Y.I., Stack M.S. Type I collagen stabilization of matrix metalloproteinase-2. Arch Biochem Biophys 2001, 390:51-56.
108. Nguyen Q., Murphy G., Hughes C.E., Mort J.S., Roughley P.J. Matrix metalloproteinases cleave at two distinct sites on human cartilage link protein. Biochem J 1993, 295(Pt 2):595-598.
109. Sasaki T., Gohring W., Mann K., Maurer P., Hohenester E., Knauper V., et al. Limited cleavage of extracellular matrix protein BM-40 by matrix metalloproteinases increases its affinity for collagens. J Biol Chem 1997, 272:9237-9243.
110. Lelongt B., Legallicier B., Piedagnel R., Ronco P.M. Do matrix metalloproteinases MMP-2 and MMP-9 (gelatinases) play a role in renal development, physiology and glomerular diseases?. Curr Opin Nephrol Hypertens 2001, 10:7-12.
111. Bell S.C., Pringle J.H., Taylor D.J., Malak T.M. Alternatively spliced tenascin-C mRNA isoforms in human fetal membranes. Mol Hum Reprod 1999, 5:1066-1076.
112. Siri A., Knauper V., Veirana N., Caocci F., Murphy G., Zardi L. Different susceptibility of small and large human tenascin-C isoforms to degradation by matrix metalloproteinases. J Biol Chem 1995, 270:8650-8654.
113. Gearing A.J., Beckett P., Christodoulou M., Churchill M., Clements J., Davidson A.H., et al. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 1994, 370:555-557.
114. Secchiero P., Gonelli A., Corallini F., Ceconi C., Ferrari R., Zauli G. Metalloproteinase-2 cleaves in vitro recombinant TRAIL: potential implications for the decreased serum levels of TRAIL after acute myocardial infarction. Atherosclerosis 2010, 211:333-336.